Leap Therapeutics is a biotechnology company focused on developing novel therapies for cancer treatment. They make money by advancing their proprietary monoclonal antibodies through clinical trials and partnering with other pharmaceutical companies for development and commercialization. Founded in 2011, Leap Therapeutics has a significant history of strategic collaborations and a robust pipeline targeting various cancer indications, including their lead product candidate, DKN-01, which targets the DKK1 protein to modulate the immune system and inhibit tumor growth.